Binds Oligosaccharide Structure Patents (Class 530/387.5)
-
Publication number: 20110318759Abstract: The inventions provides a method for immunologically determining a keratan sulfate level which method includes bringing an anti-keratan sulfate monoclonal antibody into contact with a biological sample, the anti-keratan sulfate monoclonal antibody exhibiting a relative reaction specificity between keratan sulfate-I and keratan sulfate-II represented by IC50KS-I/KS-II of 0.4 to 5, to thereby provide a signal; and detecting keratan sulfate contained in the biological sample from the signal. On the basis of the method, the invention also provides a joint disease detection method and a method for assessing the effect of a remedy for a joint disease and a candidate substance therefor. Through these methods, a very small amount of keratan sulfate contained in a sample, can be determined. Particularly, these methods can determine, at high-sensitivity and high-specificity, the total keratan sulfate including keratan sulfate-I, which have been difficult to determine through a conventional technique.Type: ApplicationFiled: December 24, 2009Publication date: December 29, 2011Applicant: SEIKAGAKU CORPORATIONInventors: Shigeyuki Wakitani, Hiroshi Fujita, Takeshi Ishimaru, Koji Yamamoto, Yasuhiro Kurahashi, Junichi Onaya, Hiroyuki Masuda
-
Publication number: 20110282035Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.Type: ApplicationFiled: June 13, 2011Publication date: November 17, 2011Inventors: Adnan M.M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
-
Patent number: 8058401Abstract: The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the Plasmodium falciparum GPI inositolglycan domain or its derivatives. The present invention is useful, inter alia, as a prophylactic and/or therapeutic treatment for disease conditions such as, for example, infection by parasites and in particular infection by Plasmodium species.Type: GrantFiled: July 13, 2009Date of Patent: November 15, 2011Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventor: Louis Schofield
-
Patent number: 8058400Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: October 22, 2007Date of Patent: November 15, 2011Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard H. Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 8048994Abstract: Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides.Type: GrantFiled: April 7, 2010Date of Patent: November 1, 2011Assignee: Immunex CorporationInventor: Peter Robert Baum
-
Publication number: 20110262441Abstract: The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and/or an anti-allergic action.Type: ApplicationFiled: October 30, 2009Publication date: October 27, 2011Applicant: Japan Science and Technology AgencyInventors: Jinichi Inokuchi, Masakazu Nagafuku, Isao Ohno, Kaori Okuyama
-
Publication number: 20110263829Abstract: Disclosed are a cell-penetrating, base sequence-specific, nucleic acid-hydrolyzing antibody, a method of preparing the same, and a pharmaceutical composition comprising the same. The antibody can be prepared by modifying a particular site of a cell-penetrating, nucleic acid-hydrolyzing antibody which lacks substrate specificity to impart sequence specificity thereto without alteration in nucleic acid-hydrolyzing ability. The antibody, when penetrating into cells by itself or ectopically expressed within cells, binds specifically to single- or double-stranded nucleic acid targets and hydrolyzes them, thus downregulating the expression of the targeted genes.Type: ApplicationFiled: November 11, 2009Publication date: October 27, 2011Applicant: AJOU UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Yong-Sung Kim, Myung-Hee Kwon, Woo Ram Lee
-
Publication number: 20110229459Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: ApplicationFiled: December 4, 2009Publication date: September 22, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Publication number: 20110217304Abstract: The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described.Type: ApplicationFiled: March 3, 2011Publication date: September 8, 2011Inventor: Geneviève Hansen
-
Patent number: 8008024Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: October 3, 2008Date of Patent: August 30, 2011Assignee: President and Fellows of Harvard CollegeInventor: Jose Halperin
-
Publication number: 20110206673Abstract: The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompassed are inhibitors of Artemin and/or related ligands, and uses for these inhibitors.Type: ApplicationFiled: June 25, 2008Publication date: August 25, 2011Inventors: Liu Dongxu, Perer Edward Lobie
-
Publication number: 20110177076Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.Type: ApplicationFiled: March 21, 2011Publication date: July 21, 2011Applicant: MEDTRONIC, INC.Inventors: Lisa Lynn Shafer, Francis Joseph Carr, James Peter Gregson, Dawn Ann Bembridge, Tim Jones
-
Publication number: 20110177614Abstract: The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.Type: ApplicationFiled: January 14, 2011Publication date: July 21, 2011Inventors: Ajit Varki, Richard B. Schwab, Vered Padler-Karavani, Nancy Hurtado-Ziola
-
Patent number: 7977104Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 27, 2006Date of Patent: July 12, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20110151521Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.Type: ApplicationFiled: January 31, 2011Publication date: June 23, 2011Applicant: Life Technologies CorporationInventors: Wu Bo Li, Joel A. Jessee, Christian E. GRUBER
-
Publication number: 20110142838Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.Type: ApplicationFiled: April 3, 2009Publication date: June 16, 2011Applicant: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Zev Wainberg
-
Publication number: 20110144309Abstract: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.Type: ApplicationFiled: November 8, 2010Publication date: June 16, 2011Applicant: Celltech R&D, Inc.Inventors: Fred Ramsdell, Sean C. Proll, Karen Staehling-Hampton, Mark W. Appleby, Leon Fernando Garcia-Martinez
-
Publication number: 20110135645Abstract: The present invention discloses methods for generating antibodies to human metapneumovirus (HMPV) polypeptides, including antibodies that immunospecifically bind to a HMPV F-protein. The invention also discloses methods for preventing, treating, or ameliorating symptoms associated with HMPV infection.Type: ApplicationFiled: October 4, 2007Publication date: June 9, 2011Applicant: The Scripps Research InstituteInventors: R. Anthony Williamson, Zhifeng Chen, Pietro Paolo Sanna, Dennis R. Burton, James Crowe, John V. Williams
-
Patent number: 7935792Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide having the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which includes an amino acid sequence including substitution, deletion, insertion or transposition of one or a few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented the formula I: GlcNAc?1-3Gal?1-4GlcNAc??(I) where GlcNAc represents an N-acetyl-glucosamine residue, Gal represents a galactose residue, ? 1-3 represents a ? 1-3 glycosidic linkage, and ? 1-4 represents a ? 1-4 glycosidic linkage.Type: GrantFiled: August 19, 2008Date of Patent: May 3, 2011Assignee: Aichi PrefectureInventor: Kenji Uchimura
-
Publication number: 20110076730Abstract: Improved enzyme systems, recombinant cells, and processes employing the same to produce biosynthetic D-1,2,4-butanetriol; D-1,2,4-butanetriol prepared thereby and derivatives thereof; D-1,2,4-butanetriol trinitrate prepared therefrom; and enzymes and genes useful in the enzyme systems and recombinant cells.Type: ApplicationFiled: July 19, 2007Publication date: March 31, 2011Applicant: Board of Trustees of Michigan State UniversityInventors: John W. Frost, Wei Niu
-
Publication number: 20110076737Abstract: This patent involves improvement of the thermal stability of natural polymers, “hydrogels”, to be used as supports for covalent immobilization of enzymes. The presence of the new functionality has been proved by FTIR. In brief, the new polymeric carrier has the main following advantages: • Natural polymer & friendly to the environment • Highly hydrophilic • Containing active groups for covalent immobilization of enzymes& antibodies Thermally stable (35-95° C.) Porous The modified carrier could be used for immobilization of enzymes on the industrial scale. The immobilized enzymes could be reused for tens of times, which will reduce the cost of the enzymes and their products.Type: ApplicationFiled: June 11, 2009Publication date: March 31, 2011Inventor: Magdy Mahmoud Mustafa Elnashar
-
Publication number: 20110064653Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: July 29, 2010Publication date: March 17, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 7893219Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for ?-1,6-glucan.Type: GrantFiled: September 14, 2005Date of Patent: February 22, 2011Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Antonio Cassone, Antonella Torosantucci
-
Publication number: 20110033452Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Publication number: 20110027182Abstract: The invention relates to a substance and a process for obtaining anti-tumor agents.Type: ApplicationFiled: July 1, 2010Publication date: February 3, 2011Inventors: Heinz-Peter Vollmers, Hans Konrad Mueller-Hermelink, Annette Buechner-Vollmers
-
Publication number: 20110002932Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: June 28, 2010Publication date: January 6, 2011Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 7850966Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.Type: GrantFiled: September 24, 2008Date of Patent: December 14, 2010Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Patent number: 7842500Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swarn tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.Type: GrantFiled: March 31, 2006Date of Patent: November 30, 2010Assignee: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
-
Publication number: 20100297130Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for (?-1,6-glucan.Type: ApplicationFiled: August 6, 2010Publication date: November 25, 2010Inventors: Antonio Cassone, Antonella Torosantucci
-
Publication number: 20100291540Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.Type: ApplicationFiled: May 12, 2009Publication date: November 18, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
-
Patent number: 7825225Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: July 24, 2009Date of Patent: November 2, 2010Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20100266596Abstract: A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease.Type: ApplicationFiled: October 2, 2008Publication date: October 21, 2010Inventor: John Cox
-
Publication number: 20100266585Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: ApplicationFiled: September 12, 2008Publication date: October 21, 2010Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20100261647Abstract: The invention provides compositions, methods, and kits for increasing transport of a neurotrophin (e.g., erythropoietin (EPO)) across the blood brain barrier while allowing its activity to remain substantially intact. The neurotrophin (e.g., EPO) is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.Type: ApplicationFiled: January 15, 2010Publication date: October 14, 2010Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20100254898Abstract: Monoclonal antibodies to carbohydrate antigens containing a terminal GalNAc?1-3Gal are provided. The antibodies of the present invention are found to specifically recognize GalNAc?1-3Gal with little cross-reactivity to other structurally similar antigens such as GalNAc?1-6Gal, blood group A, Forssman antigen and the Tn antigen on both solution assays and human tissue. Compositions comprising the monoclonal antibodies, as well as methods of diagnosis, treatment and prognostication are also provided.Type: ApplicationFiled: April 1, 2010Publication date: October 7, 2010Applicants: Human ServicesInventors: Jeffrey Gildersleeve, Zhitao Li, Qian Li, Miriam Anver, Donna O. Butcher
-
Publication number: 20100239584Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.Type: ApplicationFiled: May 16, 2008Publication date: September 23, 2010Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTESInventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
-
Publication number: 20100233174Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: ApplicationFiled: December 24, 2008Publication date: September 16, 2010Inventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Biswa Choudhury, Elmar Kannenberg, Christine Leoff, Alok Mehta, Elke Saile, Jana Rauvolfova, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
-
Patent number: 7790403Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: October 22, 2007Date of Patent: September 7, 2010Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 7767787Abstract: The invention relates to a substance and a process for obtaining anti-tumor agents.Type: GrantFiled: December 22, 1999Date of Patent: August 3, 2010Assignee: Debiovision Inc.Inventors: Heinz Peter Vollmers, Hans Konrad Mueller-Hermelink
-
Publication number: 20100178292Abstract: The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described.Type: ApplicationFiled: January 12, 2010Publication date: July 15, 2010Applicants: The Board of Trustees of the Leland Stanford Junior University, Imperial College of LondonInventors: Denong Wang, Thomas Newsom-Davis, Lawrence Steinman, Gavin Screaton
-
Publication number: 20100172899Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Publication number: 20100172906Abstract: The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.Type: ApplicationFiled: December 31, 2009Publication date: July 8, 2010Inventors: Jiann-Shiun LAI, Woan-Eng Chan
-
Patent number: 7745584Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to chondroitin sulfate, particularly CS-A, CS-C and CS-E tetrasaccharides. The present invention also relates to methods of making anti-CS antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment.Type: GrantFiled: May 22, 2007Date of Patent: June 29, 2010Assignee: California Institute of TechnologyInventors: Sarah E. Tully, Linda Hsieh-Wilson
-
Patent number: 7741442Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: September 6, 2005Date of Patent: June 22, 2010Assignee: Kyowa Hakko Kirin Co., LtdInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20100144589Abstract: The present invention provides methods of predicting the relative growth rate, replication rate, or lethality of a first malignancy as compared to another malignancy or as compared to a plurality of malignancies, including methods of predicting the relative growth rate, replication rate, or relative lethality of a primary malignancy as compared to a metastatic malignancy, including comparing the concentration of Replikin sequences in the first malignancy with the concentration of Replikin sequences in another malignancy or malignancies and further provides Replikin peptides and Replikin Peak Genes identified within a malignancy for diagnostic, therapeutic, preventive, and predictive purposes.Type: ApplicationFiled: August 7, 2009Publication date: June 10, 2010Inventors: Samuel BOGOCH, Elenore S. BOGOCH, Samuel Winston BOGOCH, Anne Elenore BORSANYI
-
Publication number: 20100137564Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide having the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which includes an amino acid sequence including substitution, deletion, insertion or transposition of one or a few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented the formula I: GlcNAc?1-3Gal?1-4GlcNAc??(I) where GlcNAc represents an N-acetyl-glucosamine residue, Gal represents a galactose residue, ? 1-3 represents a ? 1-3 glycosidic linkage, and ? 1-4 represents a ? 1-4 glycosidic linkage.Type: ApplicationFiled: August 19, 2008Publication date: June 3, 2010Applicant: Aichi PrefectureInventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Publication number: 20100104572Abstract: The present invention relates in general to the field of cancer diagnostics and treatment. In particular, the present invention provides methods for identifying diagnostic and therapeutic molecules that bind to a carbohydrate antigen on the surface of a cancer cell and induce cell death, to pharmaceutical compositions comprising the molecules and uses thereof.Type: ApplicationFiled: November 1, 2007Publication date: April 29, 2010Inventor: Sylvie Luria
-
Patent number: 7696326Abstract: The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.Type: GrantFiled: January 3, 2007Date of Patent: April 13, 2010Assignee: Institut PasteurInventors: Sylvie Bay, Daniele Cantacuzene, Claude Leclerc, Richard Lo-Man
-
Patent number: 7687609Abstract: A complex consisting of galectin-3 and chondroitin oligosaccharide and methods for seperating and detecting the chondroitin oligosaccharide in a sample using the immobilized complex.Type: GrantFiled: May 21, 2007Date of Patent: March 30, 2010Assignees: National Institute of Advanced Industrial Science and Technology, Seikagaku CorporationInventors: Toshikazu Minamisawa, Kiyoshi Suzuki, Jun Hirabayashi
-
Patent number: 7632502Abstract: An isolated surface protein known as mp58 is provided from the yeast Candida albicans which has specific active peptide and carbohydrate regions and immunogenic epitopes therein and which elicits strong antibody responses during candidiasis. Antibodies raised from mp58 and the immunogenic regions and epitopes therein are also provided which can recognize the protein and its active regions and epitopes. The protein and antibodies of the present invention will thus be useful in methods of diagnosing, monitoring, treating or preventing infection of C. albicans and other yeast, and can also provide the basis for the development of immunity-based prophylactic, therapeutic and diagnostic techniques for the identification and management of disease conditions such as candidiasis.Type: GrantFiled: April 18, 2003Date of Patent: December 15, 2009Assignee: The Board of Regents of the University of Texas SystemInventor: Jose Lopez-Ribot